Modena said the company's COVID-19 booster injections increased their antibodies against Omikejung by a factor of 36.
On Monday, Modena said in a statement that the company's 50-micrograms of MRA-1273 booster needles increased the level of neutralizing antibodies against Omicron by a factor of 36; 100 micrograms of MRA-1273 increased levels of neutralizing antibodies to Aomiqueron by about 83 times.
Modena said the experimental data were mainly based on the serum of 20 recipients of each dose-boosting needle, and the relevant experimenters measured the antibody data 29 days after the injection. High-dose booster injections are generally safe and well tolerated, and the frequency of associated side effect reactions has not increased significantly.
Moderna CEO Stephane Bancel said in a statement that the experimental data was "reassuring" and that the company would continue to develop a vaccine against the Semicon variant, which is expected to enter clinical trials in early 2022.
Affected by this news, Modena's US stocks rose nearly 6% before market hours.
Major pharmaceutical companies are actively testing the efficacy of existing vaccines against Omikeron.
The latest data from Pfizer shows that the new crown oral drug Paxlovid is still 89% effective in reducing hospitalization or mortality, and in vitro trials have confirmed that it is still effective for Omiqueron. In addition, a South African study showed that two doses of bioNTech/Pfizer vaccine were 70% effective in preventing hospital admissions in patients with Omi kerong infection.
These positive data results are released just in time for the U.S. Food and Drug Administration (FDA) to review whether to approve Paxlovid for use in high-risk adults. The researchers were pleased with the data, and Mikael Dolsten, chief scientific officer at Pfizer, said in an interview: "This is a complete victory that holds great promise for another highly effective defense virus." ”
Dolsten said he expects Paxlovid to soon be authorized by the FDA and other regulators for use in high-risk groups. Oral antiviral therapy for COVID-19 has not been approved in the United States.